Author

R. Lepore

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Bioengineering· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Approach:deep learning· 1 Organism:human· 1 Organism:rat· 1

Frequent Co-Authors

A. Pons-Grifols· 3 shared A. Valencia· 3 shared B. Clotet· 3 shared B. Trinite· 3 shared F. Tarres-Freixas· 3 shared J. Blanco· 3 shared J. Carrillo· 3 shared V. Guallar· 3 shared

Activity by Year

2021-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

A. Pons-Grifols

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Epitope Engineered Human Haematopoietic Stem Cells are Shielded from CD123-targeted Immunotherapy

R. Marone, E. Landmann, A. Devaux, R. Lepore, D. Seyres, J. Zuin, T. Burgold, C. Engdahl, G. Capoferri, A. DellAglio, C. Larrue, F. Simonetta, J. Rositzka, M. Rhiel, G. Andrieux, , L. T. Jeker

This paper shows that epitope-engineered human hematopoietic stem cells are protected from CD123-targeted immunotherapy while maintaining functionality, offering a strategy for tumor-selective therapy.

Journal of Experimental Medicine · Sep 29, 2023Peer-reviewedBioengineering

VLP-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice

A. Barajas, P. Amengual-Rigo, A. Pons-Grifols, R. Ortiz, O. Garcia Carmona, V. Urrea, N. de la Iglesia, J. Blanco-Heredia, C. Anjos-Souza, I. Varela, B. Trinite, F. Tarres-Freixas, C. Rovirosa, R. Lepore, M. Vazquez, , J. Blanco

This study develops a neoantigen selection pipeline and a VLP-based vaccine platform to enhance immunogenicity and antitumor activity in mice.

bioRxiv · Sep 7, 2023 · PreprintImmunology

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant.

J. Carrillo, C. Avila-Nieto, J. Vergara-Alert, P. Amengual-Rigo, E. Ainsua-Enrich, M. Brustolin, M. L. Rodriguez de la Concepcion, N. Pedreno-Lopez, J. Rodon, V. Urrea, E. Pradenas, S. Marfil, E. Ballana, E. Riveira-Munoz, M. Perez, , J. Segales

This paper identifies mutations that improve the production and efficacy of SARS-CoV-2 Spike proteins, protecting animal models from the Beta variant.

bioRxiv · Jul 7, 2023Immunology

SARS-CoV-2 B.1.351 (beta) variant shows enhanced infectivity in K18-hACE2 transgenic mice and expanded tropism to wildtype mice compared to B.1 variant

F. Tarres-Freixas, B. Trinite, A. Pons-Grifols, M. Romero-Durana, E. Riveira-Munoz, C. Avila-Nieto, M. Perez, E. Garcia-Vidal, D. Perez-Zsolt, J. Munoz-Basagoiti, D. Raich-Regue, N. Izquierdo-Useros, I. Blanco, M. Noguera-Julian, V. Guallar, , J. Blanco

This study shows that the SARS-CoV-2 B.1.351 variant infects K18-hACE2 mice faster and wildtype mice, with milder symptoms than the B.1 variant.

bioRxiv · Aug 3, 2021 · PreprintMicrobiology